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Abstract
Background: We evaluated BCR-ABL1 kinetics in patients treated with nilotinib and analyzed whether a dynamic
model of changes in BCR-ABL1 levels over time could be used to predict long-term responses.
Methods: Patients from the nilotinib registration trial (CAMN107A2101; registered at www.clinicaltrials.gov as
NCT00109707) who had imatinib-resistant or -intolerant Philadelphia chromosome–positive (Ph+) chronic myeloid
leukemia (CML) in chronic phase (CP) or accelerated phase with BCR-ABL1 > 10% (on the international scale [IS]) at
baseline and, in the first 6 months, had at least three BCR-ABL1 transcript measurements and an average daily dose
of at least 720 mg were included in this analysis (N = 123).
Results: More than half of patients (65/123; 53%) had a slow monophasic response and the remainder
(58/123; 47%) had a biphasic response, in which patients had a rapid initial decrease in BCR-ABL1 transcripts
followed by a more gradual response. The biphasic response type strongly correlated with improved event-free
survival (EFS). Data in the first 6 months of follow-up were sufficient to predict EFS at 24 months.
Conclusions: Unlike newly diagnosed patients with Ph+ CML-CP—in whom the majority had a biphasic
response—approximately half of patients with imatinib-resistant or -intolerant CML had a slower, monophasic
response. Second-line patients who did have a biphasic response had an EFS outlook similar to that of newly
diagnosed patients treated with imatinib. Our model was comparable to using BCR-ABL1 (IS) ≤ 10% at 6 months as
a threshold for predicting EFS.
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Background
Chronic myeloid leukemia (CML) is a clonal myelopro-
liferative disorder characterized by the expansion of
hematopoietic cells carrying the oncogenic BCR-ABL1
fusion gene. The BCR-ABL1 fusion gene is formed by a
reciprocal translocation of a fragment of the Abelson
gene (ABL1), situated at the breakpoint on chromosome
9, with a fragment of the breakpoint cluster region (BCR)
gene on chromosome 22. This translocation forms the
Philadelphia chromosome (Ph), which encodes the consti-
tutively active BCR-ABL1 protein tyrosine kinase [1,2].
Deregulated phosphorylation of protein tyrosine residues
by this constitutively active tyrosine kinase leads to activa-
tion of downstream effectors that enable growth factor–
independent proliferation and neoplastic transformation
in the transformed hematopoietic cells [3].
Imatinib is a BCR-ABL1 tyrosine kinase inhibitor
(TKI) that demonstrated superior response rates and
improved tolerability over interferon-α plus cytarabine
in the phase III open-label International Randomized
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Study of Interferon and STI571 (IRIS) trial [4]. Despite
the success of imatinib, a significant proportion of patients
discontinue therapy (34% in the IRIS trial) [5] for reasons
that include intolerance or resistance to the drug.
Nilotinib was rationally designed after the discovery of
resistance to imatinib in early clinical trials [6-8] and
laboratory evidence showing that point mutations in the
BCR-ABL1 kinase domain mutation were the most
common cause of such resistance [9]. A more potent
BCR-ABL1 kinase inhibitor was hypothesized to reduce the
reservoir of leukemic cells in patients, thereby impeding
the emergence of drug resistance. Nilotinib is approved in
more than 60 countries worldwide for the treatment of
newly diagnosed patients with Ph+CML in the chronic
phase (CP) and in patients with Ph+CML-CP and in the
accelerated phase (AP) who have failed prior therapy,
including imatinib. Approval as second-line treatment
was based on results from a phase II open-label registration
study [10] that showed durable responses and overall
survival of 87% with 24 months of follow-up [11].
Normalization of blood counts, as measured by
hematologic responses; reduction and elimination of
the Ph chromosome, as measured by cytogenetic moni-
toring; and reduction and elimination of BCR-ABL1
gene expression, as measured by real-time quantitative
polymerase chain reaction (RQ-PCR) are important
measures of treatment success. Before the routine use
of BCR-ABL1 TKIs, the evaluation of hematologic and
cytogenetic responses was sufficient to determine treatment
efficacy, as improvement in these outcomes was the
limit of response in most patients. However, with more
potent BCR-ABL1–targeting therapies, deeper responses
are achieved in most patients, necessitating more sensitive
methods of disease detection.
An abundance of literature explores the use of molecular
response to predict long-term outcome [12-18]. A common
approach is the landmark analysis, whereby a particular
threshold (e.g., BCR-ABL1 ratio ≤ 0.1% on the international
scale [IS]) and time (e.g., 3 months) are chosen, and longer-
term outcomes (e.g., progression-free survival or event-free
survival [EFS] at 2 years) are evaluated according to
whether patients attained the threshold at the landmark
time point [18-23]. While this approach is reasonable in
controlled clinical trials, challenges may arise in practice,
including missing samples or those inconsistent with prior
or subsequent samples. For example, a patient may not
have a BCR-ABL1 assessment at month 6 but may have
assessments at months 4 and 8. Or, a patient may achieve
major molecular response (MMR) at month 6, lose MMR
at month 12, and then regain MMR at month 18. Rather
than assessing a patient based on his or her response at a
single time point, using all of the information from a
patient’s full clinical history may provide a more robust
method for classifying patient response.
A mathematical model is a natural tool for integrating
information from the full BCR-ABL1 transcript dynamic
time course. Several groups have established such
models for predicting BCR-ABL1 response in patients
with CML [13,15,18]. We previously presented an approach
using standard pharmacokinetic/pharmacodynamic methods
to model the clinical data of newly diagnosed patients
treated with imatinib in the IRIS trial [18]. Here, we applied
this model to patients with CML who received imatinib
treatment that had failed because of resistance or intoler-
ance and who were subsequently treated with nilotinib in
the registration study. The objectives of this analysis were
to (1) determine whether BCR-ABL1 kinetics in patients
treated with nilotinib were similar to those in patients
treated with imatinib; (2) explore whether a model using
BCR-ABL1 as a continuous measurement could potentially
be used to predict long-term response based on short-term
data; and (3) compare such methods with simpler methods.
Methods
Patients and samples
The nilotinib registration trial (CAMN107A2101; registered
at www.clinicaltrials.gov as NCT00109707) was an open-
label, multicenter, single-arm phase II study of nilotinib
(400 mg twice daily) in patients with imatinib-resistant
or -intolerant Ph+CML-CP (N= 321; 226 imatinib-resistant,
95 imatinib-intolerant) with a median exposure to nilotinib
of 561 days [10,11]. This study was conducted in accordance
with the Declaration of Helsinki, and the protocol was
reviewed by the ethics committee or institutional review
board at each participating institution. All patients gave
written informed consent.
RQ-PCR measurements of BCR-ABL1 were taken
monthly during the first 3 months of the trial and once
every 3 months thereafter, as described previously [24]. For
this analysis, patients were required to have at least three
PCR measurements, an average daily dose of at least
720 mg (90% of the target dose) in the first 6 months of the
study, and BCR-ABL1 (IS) > 10% at baseline (n = 123).
BCR-ABL1 (IS) ≤ 10% can be measured effectively [25].
The upper limit of 10% is determined by two sources of
nonlinearity in the BCR-ABL1 ratio estimation: (1) depend-
ing on the primer design for the ABL1 control gene, both
ABL1 and BCR-ABL1 are amplified when the BCR-ABL1
levels are high [26]; and (2) healthy cells have two copies of
the BCR and ABL1 control genes, while leukemic cells
have one control gene and one BCR-ABL1 gene. There is
no simple formula that can be applied to remove this
nonlinearity because expression rates of the control genes
may be different at the time of diagnosis and at the time
that a patient achieves a good response. Thus, while mea-
surements above 10% are included in this analysis so that
we can describe the full range of BCR-ABL1 dynamics for
all patients, quantitative values of the parameters governing
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the dynamics at the start of treatment (A, α, μ; see
model below) should be considered qualitatively.
Model selection and parameter fitting
The time course of BCR-ABL1 transcript levels was
modeled using nonlinear mixed effects (NLME) meth-
odology. This is an accepted approach for deriving
population models from clinical data [27,28]. We used
maximum likelihood methods, as implemented in Monolix
(http://www.lixoft.com/wp-content/resources/docs/
UsersGuide.pdf ) NLME software in MATLAB (The
MathWorks, Inc., Natick, MA), to fit the following
between-patient mixture model to the log10 of the BCR-
ABL1 ratios measured at time t, R(t), where treatment be-
gins at t = 0:
R tð Þ ¼
log10 Aeμtð Þ þ ε Slow BCRABL
response with probability p
log10 Aeαt þ Beβt
 þ ε Fast BCRABL
response with probability 1p
8>><
>>:
The model represents two typical profiles: (1) slow
responders with a monophasic decline, who typically had
little if any decline in BCR-ABL1 (IS)% (at rate μ), and (2)
fast responders with a biphasic decline, in whom a rapid
initial decrease in the BCR-ABL1 (IS)% (at rate α) was
followed by a more gradual response (at rate β) that could
be either increasing or decreasing. A similar version of the
above model was used to fit patients from the IRIS study
[18], although we excluded the triphasic mixture population
due to limited follow-up time (2 years) in the present study.
The constant terms (A, B) were restricted to be greater
than zero because BCR-ABL1 (IS)% is always positive. The
rate constants (μ, α, β) have units of 1/year. Before treat-
ment starts, the log10 of the BCR-ABL1 (IS)% is assumed to
be log(A) or log(A + B) with additive measurement error.
The model has an additive residual error term (ε) in log
space that describes variability in the measurement due to
assay and interoccasion variability and model error. All
mono- or biexponential parameters (A, B, α, β, μ) were
treated as mixed effects with both a fixed component that
represents the typical value for the population and a ran-
dom component that represents the interpatient variability.
The mixture probability p was a fixed effect. The constant
terms (A, B) were chosen from a log-normal distribution
because BCR-ABL1 (IS)% is always greater than zero
(e.g., A = θΑ*exp(ηΑ), where ηΑ is normally distributed with
mean zero and variance ωA). Similarly, both α and μ are
always less than or equal to zero and so are chosen from a
log-normal distribution with a negative fixed-effect term
(e.g., θα < 0). Thus, we have α = θα*exp(ηα). Finally, we
chose β from a normal distribution, allowing it to be either
negative or positive (i.e., β = θβ + ηβ).
We used 0.0032% (a 4.5-log10 decrease in the BCR-
ABL1 [IS]%) as the minimal level of detection of the
PCR assay for all laboratories and treated these mea-
surements as left-censored data. BCR-ABL1 transcript
levels below 0.0032% were established as “undetectable” in
the IRIS trial [29], and BCR-ABL (IS) ≤ 0.0032% has subse-
quently been defined as molecular remission at 4.5 logs
(MR4.5) [30,31]. Rather than remove all measurements
below the limit of quantitation or fix them at a certain
value, we used the M3 maximum-likelihood approach
[32], which treated any measurement falling below the
limit of detection as having an upper boundary of 0.0032%
to make optimal use of all measurements.
The maximum-likelihood approach yields informa-
tion about both the population and each individual
patient. For the population, the typical model param-
eters (A, B, μ, α, β, p) and the interpatient variability
(of A, B, μ, α, β) were estimated. In addition, for each
individual, the most likely set of parameters that describe
that individual was estimated, along with the patient’s BCR-
ABL1 response classification (slow vs. fast). In particular,
each patient was categorized as a fast or slow responder
based on the best description of that patient as calculated
by the maximum-likelihood method. For the biphasic
patients, we also computed the transition time at which
the patient transitioned from the α to the β phase of the
decline. We defined the transition time as the point of
maximum curvature of the fitted BCR-ABL1 transcript
profile, where curvature was defined in the differential
geometrical sense as κ(t) = |R”(t)|/(1 + R’(t)2)3/2.
Response prediction and model comparison
We then tested the ability of the model to predict the
event status of individual patients at year 2 from data in
the first 1, 3, 6, 9, 12, and 18 months. EFS was defined as
the time between randomization and any of the following
events on treatment: death due to any cause, progression
to AP or blast crisis, loss of complete hematologic
response, or loss of major cytogenetic response. For each
landmark time, patients who progressed or died before
that time were excluded from the analysis.
Categorization was performed by fixing the average
model parameters for the population (A, B, μ, α, β, p)
and then using the data from baseline to the landmark
time of interest to estimate the individual parameters
and response classification (fast vs. slow responder) for
each patient. When fewer than 6 months of data were
used, the long-term response parameters B and β were
not estimable, in which case the model naturally assumed
the population estimates for each patient. Because the
purpose of this analysis was to categorize each patient
as a fast or slow responder, the estimation of the long-term
response was not essential.
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Finally, we compared the models’ ability to predict
event status at 2 years based on a single BCR-ABL1
transcript measurement at 3 or 6 months, respectively.
We predicted each patient’s event status by whether the
BCR-ABL1 levels were above or below a particular
threshold at a particular landmark time. The thresholds
used were BCR-ABL1 (IS) > 10%, > 1%, and > 0.1%, and
the landmark times were 3 and 6 months. The models
were compared according to the percentage of patients
who were correctly classified, the positive predictive
value (PPV; proportion of nonprogressing patients cor-
rectly classified as nonprogressing), and the negative
predictive value (NPV; proportion of progressing pa-
tients correctly classified as progressing). In this case,
we restricted the analysis to the 76 patients who did
not progress by month 6 and whose event status by
year 2 was known.
Results
Of the total 123 patients analyzed, 65 (53%) were catego-
rized as slow monophasic responders and 58 (47%) as fast
biphasic responders (Figures 1A and 1B). Individual fits to
16 representative patients are shown in Figure 2. Note that
some patients (patients 14 and 15) obtained an undetect-
able level of transcripts before transitioning to the β phase.
The model accounts for these patients by treating them as
biphasic responders with a β phase below the limit of
quantification of the assay, although the true dynamics
below 0.0032% BCR-ABL1 are unknown.
The parameter p was estimated accordingly to be 51% ±
10%, differing significantly from IRIS, where the probability
of a monophasic response was only 14%. However, the
other model parameters were all comparable, with typical
values of: θA,IRIS = 34%, θA,2101 = 45%; θB,IRIS = 0.09%,
θB,2101 = 0.05%; θμ,IRIS = −0.1/year, θμ,2101 = −0.2/year;
θα,IRIS = −14/year, θα,2101 = −17/year; θβ,IRIS = −0.5/year,
θβ,2101 = −0.6/year [18]. In addition, the variances on
the parameters from 2101 were ωA = 0.4, ωB = 8.8, ωμ = 1.4,
ωα = 0.3, ωβ = 0.3. The large variability in B indicates
that the β-phase transition for the biphasic patients
can occur over a large range of BCR-ABL1 values, from
below 0.0032% (undetectable) to 7%. The initial response
rate—which was equal to μ for the slow responders and α
for the fast responders—had a bimodal distribution, with a
threshold of approximately −2 to −6/year separating the
two distributions (Figure 1C).
A fast biphasic response, according to the model,
was associated with the best hematologic, cytogenetic,
and molecular responses by 24 months, and patients
classified as fast responders were more likely to be
considered optimal responders according to European
LeukemiaNet criteria [33] (Table 1). Furthermore, slow
monophasic responders were more likely to be imatinib-
resistant (as opposed to imatinib-intolerant) and have
nilotinib-insensitive mutations (half maximal inhibitory
concentration [IC50] > 150 nm; Y253H, E255V/K, F359V/C)
[24] in BCR-ABL1 at baseline (Table 2).
A small number of patients achieved a fast response
without a detectable β phase. These patients had small
estimated B values, indicating that the transition from
the α to the β phase occurred below MR4.5. The true
BCR-ABL1 dynamics below MR4.5 cannot be accurately
determined at present.
The EFS outcomes of the two responder groups are
shown in Figure 3, overlaid with the EFS for newly
diagnosed patients with CML in the IRIS trial. Fast
responders on second-line nilotinib had higher EFS rates
than did slow responders and had a comparable outlook
to that of a typical patient on frontline imatinib.
Assuming the same average population parameters
with different landmark times, we assessed the ability of
the model to predict EFS at 2 years. At a landmark time
of 6 months, the model showed a statistically significant
difference in EFS between patients classified as slow
(monophasic) and fast (biphasic) responders (Figure 4A).
We changed the follow-up time in the model from 1 month
to 18 months and found that the classification improved
up to month 6, but after that there was no improvement
in the percentage of patients correctly classified as having
progressed (Figure 4B). The median time to transition
from the α to the β phase for biphasic patients was
6.1 months, with 66% of these patients having a transition
point between months 4 and 8 (Figures 4C and 4D).
The mean BCR-ABL1 ratio at the time of the transition
was 0.035%.
Finally, we compared model classification to other
predictive measures of patient response, in particular,
the molecular response at 3 and 6 months (Table 3).
We found that the model classification had the highest
percentage of correctly classified patients as well as the
highest NPV. However, the improvement shown in the
model-based classification over a simpler classification
method—one categorizing patients based on whether their
BCR-ABL1 (IS) was above or below 10% at 6 months—was
not substantial (2.6%). We also found that the model using
6 months of follow-up was more accurate at predicting EFS
at 2 years than the model using 3 months of follow-up.
Discussion
A model-based analysis was previously developed to
classify patients from the imatinib arm of the IRIS trial
into three main categories: (1) slow monophasic patients
who either do not respond to therapy or exhibit a very
gradual BCR-ABL1 decline; (2) fast biphasic patients
with an initial rapid decline in BCR-ABL1 during the
first 6 months of therapy, followed by a more gradual
decline; and (3) fast triphasic patients who follow the
biphasic trend but relapse 2 to 4 years into treatment,
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exhibiting a rapid rise in BCR-ABL1 [18]. Because second-
line patients treated with nilotinib in the registration trial
have only been followed for 2 to 3 years thus far, the
triphasic patients have been difficult to detect. Thus, we
applied a scaled-down version of the model that categorized
patients as either slow or fast BCR-ABL1 responders.
Patients were nearly evenly divided between the slow
monophasic population (65/123; 53%) and the biphasic
population (58/123; 47%). This was in contrast to the
IRIS trial [18], where the vast majority of patients
exhibited a biphasic response. However, the biphasic
patients in the nilotinib registration trial had a similar
EFS outlook to that of newly diagnosed biphasic patients
in the imatinib arm of the IRIS trial, and the model
parameters describing the monophasic and biphasic
parameters were similar for IRIS and the nilotinib
registration trial. This could be because the resistance
to imatinib was overwhelmed by the more potent BCR-
ABL inhibition by nilotinib and/or because "resistance"
was actually intolerance or nonadherence, whereby patients
did not take imatinib daily. Thus, some of the nilotinib
biphasic responders may have actually been patients
intolerant to or nonadherent with imatinib who might
have been responders had they remained adherent to
their medication.
The biphasic response type strongly correlated with
improved EFS, as in IRIS. In addition, for this patient
subpopulation, a 6-month follow-up time was optimal
for predicting EFS at 24 months. This coincides with the
observation that the transition time from the α to the
β phase in biphasic patients typically occurs between
months 4 and 8. Additional measurements at later times
were of limited value for prediction based on model
categorization. The median transition time at 6 months, at
a median transition depth of 0.035% BCR-ABL1 (IS), also
provides insight into why using a single measurement at
6 months outperforms using a measurement at 3 months.
This level of response—nearly a 4-log reduction in BCR-
ABL1 from standardized baseline—is a deeper response
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Figure 1 BCR-ABL1 (international scale [IS])% for all 123
patients in this analysis, divided into two groups, with an
example patient shown in black within each group: (A) slow
monophasic responders (n = 65) with μ = −0.4/year for the
example patient and (B) fast biphasic responders (n = 58) with
α = −15.1/year and β = −0.9/year for the example patient. The
μ*, α*, β* parameters are shown for the example patient, where
μ* = μlog10e, α* = αlog10e, and β* = βlog10e. The asterisks (*)
indicate when a BCR-ABL1 (IS)% measurement fell below 0.0032%
(= 100 × 10-4.5), the approximate limit of quantitation of the assay
for all laboratories in the International Randomized Study of
Interferon and STI571 trial; (C) histogram of the initial reduction
rates μ and α. Note that there is no overlap between the two
populations and that the vertical dashed line at −3/year
demonstrates where the separation occurs.
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than MMR (BCR-ABL1 [IS] ≤ 0.1%), and achieving such a
response has been associated with excellent long-term
outcomes [22,23,34].
These findings are consistent with other studies showing
that early molecular responses were associated with
superior EFS and overall survival [22,35-37]. These
landmark analyses, most in frontline patients treated
with imatinib or imatinib-based combinations, typically
focused on responses at 3 months as a predictor of
later responses. Recent data from patients who received
second-generation TKIs as second-line treatment at the
Hammersmith Hospital in London revealed that molecular
responses at 3 months were predictive of overall survival
[38]. Another landmark analysis of imatinib-resistant
or -intolerant patients enrolled in the nilotinib registration
trial showed that molecular responses at 3 months
predicted EFS at 24 months [21], but did not compare the
utility of 3- versus 6-month BCR-ABL levels. A recent
evaluation of frontline dasatinib suggested that the predict-
ive value of the 3-month landmark could be improved with
drug-specific BCR-ABL cutoffs [39].
We note that it may seem counterintuitive to use this
model to categorize a patient as a fast biphasic re-
sponder when only 3 to 6 months of data is available,
and the β phase is not yet observable. In using the bi-
phasic model even in the presence of limited information,
Table 1 Patient response by model response type
Best response achieved over 24 months, n (%) ELN response at 12 months, n (%)
Response type All patients, n CHR CCyR MMR Optimal Suboptimal Warning or failure Not assessable
Slow (monophasic) 65 47 (72.3) 5 (7.7) 1 (1.5) 2 (3.1) 2 (3.1) 39 (60.0) 22 (33.8)
Fast (biphasic) 58 57 (98.3) 51 (87.9) 41 (70.7) 40 (69.0) 7 (12.1) 4 (6.9) 7 (12.1)
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Figure 2 Individual fits to 16 patients. Patients 1 to 8 are slow monophasic, and patients 9 to 16 are fast biphasic. The asterisk (*)
represents measurements below the limit of quantification of the assay.
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we are making use of prior information from both IRIS as
well as this study, where almost all fast responders ultim-
ately have a β phase. Furthermore, in some cases, the β
phase does occur before month 6 (Figure 4D), so account-
ing for this second slope may be important for these
patients.
Because the definition of the transition point as the
point of maximum curvature was somewhat complex,
we initially tested simpler definitions for the transition
point, such as the point of maximum second derivative
(R″(t)), or the point where Aeαt = Beβt. We found that the
point of maximum curvature definition most consistently
agreed with our estimation of where the transition point
should lie based on clinical experience.
The model used in this study was not superior at
predicting the longer-term event status of individual
patients versus using BCR-ABL1 (IS) above or below 10%
at 6 months. Furthermore, the NPV of all the classifiers in
the model was relatively low (maximum of 62%). This may
be due in part to 2 years of follow-up being too short and
that, over longer times, the monophasic patients may
continue to be more likely to progress than the biphasic
patients. The NPVs and PPVs depend on the prevalence of
second-line patients who do not respond well to nilotinib
therapy; this prevalence may be lower in a controlled trial
than in the general population. Nevertheless, PPV and NPV
are preliminary tools for comparing the predictive power of
different methodologies. Our modeling approach represents
one of many classification schemes that can be used for
dividing a population into two groups. In the future, we
could consider exploring other classification approaches,
such as neural networks or support vector machines.
Key benefits of the modeling approach (classification of
a second-line patient as either a fast or slow responder)
are that (1) the model helps to identify 6 months as an
ideal follow-up time; and (2) the model provides a natural
means for incorporating all measurements and treating
the BCR-ABL1 dynamics as a continuous variable up to
the time at which classification takes place. In the clinic,
samples may be missed or multiple conflicting measure-
ments may be obtained in the same time period. In these
instances, a simple algorithm may not be able to adequately
determine patient response based on one data point at a
particular time. The model, however, provides a natural
technique for integrating missing data and multiple samples
at the same time, and produces a dichotomous classifica-
tion associated with EFS. While we required patients to
have at least three data points in the first 6 months, the
NLME approach used here can work with fewer data points
such that a patient with only one assessment at month 6
could be classified as a fast responder if he or she has
achieved BCR-ABL1 (IS) ≤ 0.1% (at least MMR) or a slow
responder if his or her BCR-ABL1 levels are above 10%.
In the future, it will be useful to investigate how the
model performance changes depending on the amount
of data collected.
A related modeling approach that also treated BCR-ABL1
response as a continuous parameter was recently reported
[40]. In this model, BCR-ABL1 doubling time was used to
characterize relapse rate. Patients entering blast crisis had
similar BCR-ABL1 doubling times to patients discontinuing
therapy, whereas patients with BCR-ABL–resistant muta-
tions who remained inCP had a longer time to relapse. These
differences in the velocity of leukemic cell growth were not
always evident by the BCR-ABL1 fold rise, which was
dependent on the time between measurements.
The nilotinib registration trial demonstrated high rates of
major cytogenetic response (59%) and complete cytogenetic
response (CCyR; 44%) [11]. Most patients who achieved
CCyR also achieved MMR (56%), and cytogenetic responses
were durable, with 84% of patients who achieved CCyR
maintaining response at 24 months. The overall survival at
24 months was 87%. Here, we showed that the EFS rates of
fast responders to nilotinib were comparable to those
Table 2 Patient baseline characteristics by model response type








Slow (monophasic) 65 21 (32.3) 18 (27.7) 58 (89.2) 7 (10.8)
Fast (biphasic) 58 18 (31.0) 2 (3.4) 42 (72.4) 16 (27.6)
* Half maximal inhibitory concentration (IC50) ≤ 150 nm.
† IC50 > 150 nm; Y253H, E255V/K, F359V/C.
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Figure 3 Event-free survival (EFS) according to patient group.
The Kaplan-Meier plot of the imatinib arm of the International
Randomized Study of Interferon and STI571 (IRIS) trial for frontline
patients with chronic myeloid leukemia is also shown, to illustrate
that biphasic responders do approximately as well as patients
receiving frontline imatinib treatment.
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Figure 4 (A) Event-free survival (EFS) at 2 years based on patient classification using only the first 6 months of data. The difference
between the EFS curves was found to be statistically significant at p = 0.0001 by a log-rank test; (B) the percentage of patients correctly classified
as having an event at year 2 as a function of the amount of data used to classify each patient; (C) example patient: the ✩ indicates the transition
point, defined as the point of maximum curvature where fast responders transition from the α to the β phase; the * corresponds to measurements
below the limit of quantification of the polymerase chain reaction assay, assumed to be 0.0032% for all labs; (D) histogram of transition times
between the α and β phases. Abbreviation: IS = international scale.
Table 3 Comparison of different categorization methods for predicting event-free survival at 2 years in patients alive
and event free at 6 months (n = 76)
Follow-up time for subpopulation
predicted to progress
N (above, below) threshold








> 10% BCR-ABL 32, 44 67.1 81.8 46.9
> 1% BCR-ABL 51, 25 52.6 84.0 37.3
> 0.1% BCR-ABL (MMR) 63, 13 44.7 92.3* 34.9
6 months
> 10% BCR-ABL 26, 50 75.0 84.0 57.7
> 1% BCR-ABL 38, 38 64.5 84.2 44.7
> 0.1% BCR-ABL (MMR) 50, 26 56.6 88.5 40.0
Slow (monophasic) responders 27, 49 77.6* 86.0 61.5*
Abbreviation: MMR =major molecular response.
* The number in bold indicates the highest score for that column.
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observed with newly diagnosed patients treated with
imatinib, and that BCR-ABL1 dynamics in the first 6 -
months of therapy were useful in predicting such
responses.
This work represents an exploratory step in using a
model to measure response based on BCR-ABL1 as a
continuous variable and transform it into a dichotomous
classification associated with EFS. Because the patient
subpopulation in this study was highly heterogeneous
and the subpopulation used to compare different predictors
was small (n = 76), more testing and validation will be
necessary before this approach can be directly applied
in the clinical setting.
Conclusions
Landmark analyses, in which longer-term outcomes are
analyzed according to achievement of molecular mile-
stones at early time points (3 and 6 months), have be-
come an increasingly common means of evaluating
responses to both front- and second-line TKI therapies
used for the treatment of CML. However, this emphasis
on achieving specific molecular targets may be challen-
ging in routine clinical practice, where samples are fre-
quently missing. Here, we described a mathematical
model that utilizes the full BCR-ABL1 transcript pro-
file to predict longer-term responses among patients
treated with nilotinib after imatinib failure. Evaluating
BCR-ABL1 transcript dynamics over time in an individ-
ual patient may provide a more robust and practical
method for classifying patient response.
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